methyl-[4-(5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl)benzyl]carbamic acid tert-butyl ester | 887138-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl-[4-(5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl)benzyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl methyl(4-(5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-benzyl)carbamate；tert-butyl N-methyl-N-[[4-(5-oxo-1H-1,2,4-triazol-4-yl)phenyl]methyl]carbamate
• CAS: 887138-69-4
• 化学式: C₁₅H₂₀N₄O₃
• 分子量: 304.349
• InChiKey: FJFSWVKWNIVJQH-UHFFFAOYSA-N

物化性质

• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl-[4-(5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl)benzyl]carbamic acid tert-butyl ester 在 盐酸 、 potassium carbonate 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(2-Chlorophenyl)methyl]-4-[4-(methylaminomethyl)phenyl]-1,2,4-triazol-3-one
  参考文献：
  名称：

  Structure-Based Optimization of Azole Antifungal Agents by CoMFA, CoMSIA, and Molecular Docking

  摘要：

  In a continuing effort to develop highly potent azole antifungal agents, the three-dimensional quantitative structure-activity relationship methods. CoMFA and CoMSIA, were applied using a set of novel azole antifungal compounds. The binding mode of the compounds at the active site of lanosterol 14 alpha-demethylase was further explored using the flexible docking method. Various hydrophobic, van der Waals,pi-pi stacking, and hydrogen bonding interactions were observed between the azoles and the enzyme. Based on results from the molecular modeling, a receptor-based pharmacophore model was established to guide the rational optimization of the azole antifungal agents. Thus, a total of 57 novel azoles were designed and synthesized by a three-step optimization process. In vitro antifungal assay revealed that the antifungal activities of these novel azoles were greatly improved, which confirmed the reliability of the model from molecular modeling.

  DOI：

  10.1021/jm051211n
• 作为产物：
  描述：

  4-(N-methyl-N-tert-butoxycarbonylaminomethyl)phenylsemicarbazide 、 醋酸甲脒 在 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 以82.2%的产率得到methyl-[4-(5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl)benzyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Structure-Based Optimization of Azole Antifungal Agents by CoMFA, CoMSIA, and Molecular Docking

  摘要：

  In a continuing effort to develop highly potent azole antifungal agents, the three-dimensional quantitative structure-activity relationship methods. CoMFA and CoMSIA, were applied using a set of novel azole antifungal compounds. The binding mode of the compounds at the active site of lanosterol 14 alpha-demethylase was further explored using the flexible docking method. Various hydrophobic, van der Waals,pi-pi stacking, and hydrogen bonding interactions were observed between the azoles and the enzyme. Based on results from the molecular modeling, a receptor-based pharmacophore model was established to guide the rational optimization of the azole antifungal agents. Thus, a total of 57 novel azoles were designed and synthesized by a three-step optimization process. In vitro antifungal assay revealed that the antifungal activities of these novel azoles were greatly improved, which confirmed the reliability of the model from molecular modeling.

  DOI：

  10.1021/jm051211n

文献信息

• Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis
  作者：Guiyan Han、Na Liu、Chenglan Li、Jie Tu、Zhuang Li、Chunquan Sheng

  DOI：10.1021/acs.jmedchem.0c00102

  日期：2020.5.28

  develop novel strategies and effective therapeutic agents to combat drug resistance. Herein, the first generation of lanosterol 14α-demethylase (CYP51)-histone deacetylase (HDAC) dual inhibitors was designed, which exhibited potent antifungal activity against azole-resistant clinical isolates. In particular, compounds 12h and 15j were highly active both in vitro and in vivo to treat azole-resistant

  侵袭性真菌感染（尤其是念珠菌病）在全球范围内正在作为严重的传染病出现。由于严重的抗真菌药耐药性，目前用于念珠菌病的治疗方法的疗效有限，并且死亡率高。然而，开发新的策略和有效的治疗剂以对抗耐药性是极富挑战性的。在此，设计了第一代羊毛甾醇14α-脱甲基酶（CYP51）-组蛋白脱乙酰基酶（HDAC）双重抑制剂，该抑制剂对唑类耐药临床分离株表现出有效的抗真菌活性。特别地，化合物12h和15j在体外和体内对治疗吡咯抗性念珠菌病均具有高活性。抗真菌机制研究表明，它们的作用是阻断真菌中麦角固醇的生物合成和HDAC催化活性，抑制外排泵的功能，酵母菌到菌丝的形态转变和生物膜形成。因此，CYP51-HDAC双重抑制剂代表了一种开发新颖的抗唑类念珠菌病抗真菌药的策略。